Cis-platin, vindesine, doxorubicin and cyclophosphamide in the treatment of non-small cell bronchogenic carcinoma.
Athanassiades
P
P
Department of Clinical Therapeutics, Athens University, Alexandra Hospital, 115-28 Athens, Greece.
Lagoudis
M
M
Kostis
E
E
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014751:Vindesine / Q000008:administration & dosage
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D014751:Vindesine